Venkatesan Jay
SEC-identified person · CIK 1413350 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Serina Therapeutics, Inc. SER | Director | filed 2025 - 2026 |
| Elicio Therapeutics, Inc. ELTX | Director · See Remarks | filed 2021 - 2025 |
| Nivalis Therapeutics, Inc. NVLS | Director · President | filed 2017 - 2022 |
| Max-1 Acquisition Corp XCUR | Director | filed 2017 - 2020 |
| Lion Biotechnologies, Inc. N/A | Director | filed 2013 - 2017 |
| Oncothyreon Inc. ONTY | EVP and General Manager | filed 2011 - 2014 |
| Insmed Inc INSM | Officer | filed 2012 - 2012 |
| Plasmatech Biopharmaceuticals INC accp.ob | Officer | filed 2011 - 2012 |
| Targanta Therapeutics Corp. TARG | Director | filed 2007 - 2008 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.